Of note is the dual inhibitor NVP-BEZ235, which elicits a rapid reduction in RA-FLS proliferation through blockade of the PI3K/mTOR axis, as well as combined regimens with IL-22 that suppress pathological activation [27]. The gene discussed is MTOR; the disease is rheumatoid arthritis.